Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
3.01 USD +0.67% Intraday chart for Relmada Therapeutics, Inc. +0.67% -27.29%
Jul. 01 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index CI
Jul. 01 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index
CI
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
PR
Transcript : Relmada Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 11:20 AM
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR
Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target
MT
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
PR
Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
MT
Relmada Therapeutics Provides Corporate Update
PR
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. News Relmada Therapeutics, Inc.